Martin Hasselblatt

University Hospital Münster
Country flagGermany
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (3)

Postnatal development is a critical period for the maturation of the nervous and immune systems. The choroid plexus (CP) within the brain ventricles guides brain development through the production of cerebrospinal fluid and responds to stimuli from its local immune microenvironment. Here, using single-cell sequencing, we chart the establishment of the immune niche within the CP from birth to adulthood. We demonstrate that the CP is an active site for the development of B cells from early pro-B cells to mature B cells. We also characterize a transient population of CP mast cells that is highly abundant in the perinatal period. Single activation of these cells shortly after birth led to activation of serotonin-dependent secretion from the CP epithelial cells and resulted in cognitive impairment later in life. Our findings highlight the crucial nature of the CP as a neuroimmune interface, where cellular crosstalk regulates key functions of CP activity, thereby guiding brain development.

Year:

2025

FGFR1 genetic alterations are associated with human diseases, including brain tumors. We reported multiple FGFR1 mutations in familial and sporadic cases of low-grade glioneuronal tumors, suggesting intrinsic mechanisms of selective pressure toward FGFR1 multiple events arising in the context of a quiet genome. To decipher the molecular mechanisms triggered by multiple FGFR1 mutations, we have mapped the proximal interactome of wild-type, single-and double-mutant FGFR1 proteins through a BioID-MS approach. Our data reveals novel oncogenic functionality for the two hotspots N546K and K656E, linked to evasion of lysosomal degradation. We identified a modulatory role played by the susceptibility variant R661P, which hampers the oncogenic potential of both hotspot mutations by rescuing receptor degradation and reducing N546K affinity for the downstream effector PLCγ. The R661P variant alone abolished the self-renewal capacity of oligodendroglioma cells and showed downregulation of genes involved in neurodevelopment and neuro-glial cell fate decisions, both aspects overcome in the double mutants. This study sheds light on the oncogenic effects associated with FGFR1 alterations and their recurrence in low-mutation burden and therapy naïve tumors.

Year:

2025

Background Intracerebral schwannomas are rare tumors resembling their peripheral nerve sheath counterparts but localized in the central nervous system (CNS). They are not classified as a separate tumor type in the 2021 World Health Organization classification. This study aimed to compile and characterize these rare neoplasms morphologically and molecularly. Methods We analyzed 20 tumor samples by histology, RNA next-generation sequencing, DNA-methylation profiling, copy number analyses, and single-nucleus RNA sequencing (snRNA-seq). Clinical data, including age, sex, and disease progression, were collected. Magnetic resonance imaging (MRI) series were included when available. Results All cases with tissue available for histology review (n = 13) were morphologically consistent with intracerebral schwannoma, but differed in their extent of glial fibrillary acidic protein staining. All (n = 20) shared DNA-methylation profiles distinct from other CNS tumors, as well as from Vestigial-like family (VGLL)-altered peripheral nerve sheath tumors. Most cases (n = 14/17) harbored fusions of either Vestigial-like family member 3 (VGLL3) or Vestigial-like Family member 1 (VGLL1) (CHD7::VGLL3 [n = 9/17] and EWSR1::VGLL1 [n = 5/17]). In 2 cases, the presence of a VGLL3 fusion was also confirmed by copy number analyses (n = 2/17). MRI (n = 4) showed well-defined, nodular tumors with strong, homogeneous enhancement and no diffusion restriction. Tumors were located throughout the neuroaxis (supratentorial [n = 15], infratentorial [n = 4], and spinal [n = 1]). snRNA-seq of a VGLL1-fused tumor indicated VGLL1 upregulation in 28.6% of tumor cells (n = 1). During a median follow-up of 1.8 years (range 3 months-9 years), none of the tumors recurred (n = 10). Conclusions We identify and define a new benign tumor class, designated VGLL-altered intraparenchymal CNS schwannomas. These tumors feature VGLL alterations and a specific DNA-methylation profile, with schwannoma-like histopathology and CNS localization, akin to previously classified intracerebral schwannomas.

Year:

2024

Collaborators (17)

Simon Paine

University of Nottingham

UNITED KINGDOM
View details

Matija Snuderl

Assistant Professor (Clinical) of Pathology

NYU School of Medicine

UNITED STATES
View details

Christine Stadelmann

-

GERMANY
View details

Sebastian Brandner

University College London

UNITED KINGDOM
View details

Arie Perry

University of California, San Francisco

UNITED STATES
View details

Albert A Antolin

Group Leader, AI-Driven Drug Discovery Group

Vall d'Hebron Institute of Oncology

SPAIN
View details

Nada Jabado

Professor

McGill University

CANADA
View details

Barbara Rivera

Associate Professor

Institut Quimic de Sarria

SPAIN
View details

Samir Ali-Moussa

Institut Pasteur

FRANCE
View details

Olivier Mirabeau

Institut Pasteur

FRANCE
View details

Jean-François Côté

Research Professor

Institut de recherches cliniques de Montréal

CANADA
View details

Felix Sahm

University Hospital Heidelberg

GERMANY
View details

Christian Thomas

University Hospital Münster

GERMANY
View details

Xinzhong Dong

Professor

Johns Hopkins University

UNITED STATES
View details

Nicolas Gaudenzio

Principal Investigator

INSERM Délégation régionale Midi-Pyrenees Limousin

FRANCE
View details

Jonathan Boulais

Institut de recherches cliniques de Montréal

CANADA
View details

Anne-Claude Gingras

Professor (since 2015; previously Assist and Assoc Prof)

University of Toronto

CANADA
View details